Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, oral JAK inhibitors were found to be significantly more effective than placebo in promoting hair regrowth among adults and adolescents with moderate-to-severe alopecia areata, although they were associated with an increased risk of adverse events.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This review discusses the efficacy, safety, and practical aspects of using Janus kinase inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—as treatments for severe alopecia areata in an advanced practice provider context, without reporting specific study results.

In this study, researchers found that microinfusion of dutasteride using the MMP® technique did not show a statistical difference compared to placebo in clinical assessments for male androgenetic alopecia, though patients reported improvements in the vertex area.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

This creative piece by Christa Fairbrother poetically explores the experiences of living with arthritis, with no new research findings reported.

This letter discusses the potential of the Janus kinase 1 inhibitor abrocitinib for treating oral lichen planus but provides no new research findings.

This source reports that recent research highlights the effectiveness and tolerability of oral JAK inhibitors for treating moderate to severe alopecia areata, although further placebo-controlled studies are needed to confirm their long-term safety and efficacy.

This study found that additive discourse markers were the most frequently used type in a sampled news article from The Jakarta Post.

This study evaluated the use of Jet Peel technology, a non-invasive hydroporation method, in treating androgenetic and telogen effluvium alopecia, finding improvements in hair growth and thickness, and a reduction in associated scalp conditions.

This protocol paper details methods for live imaging and analysis of dividing germline stem cells in C. elegans and reports no new research findings.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

This study found that Black patients with alopecia areata showed an average 20% reduction in scalp involvement after JAK inhibitor therapy, indicating positive treatment outcomes in this group.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

This study found that a gelatin microparticle-containing self-microemulsifying formulation combined with Soluplus improved the oral absorption of dutasteride.

In this systematic review and meta-analysis on participants aged 12 and under with alopecia areata, the authors provide supplementary tables and figures, including pooled outcomes for hair regrowth and safety of oral Janus kinase inhibitors, supporting the main findings on their effectiveness and safety.

This study found that while DALL-E 2 can create realistic hair images from text prompts, its accuracy in depicting specific hair disorders, like alopecia areata, often falls short, highlighting the need for AI developers to work with medical experts to improve dermatological applications.

Among women with androgenetic alopecia, this study observed that using Jet Peel™ with JetCare® serum led to significant trichoscopic changes, high satisfaction, and good safety after five weeks, suggesting it as a viable additional treatment option.

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

This abstract contains subscription and access information for Wolters Kluwer Health journals but reports no research findings.

This review covers the use of JAK inhibitors in treating various dermatological conditions, emphasizing their potential while noting ongoing safety concerns with oral treatments; no new clinical results are provided.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.